India
· Delayed Price · Currency is INR Eris Lifesciences Statistics
Total Valuation
Eris Lifesciences has a market cap or net worth of INR 189.99 billion. The enterprise value is 210.16 billion.
| Market Cap | 189.99B |
| Enterprise Value | 210.16B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Eris Lifesciences has 136.11 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Shares Outstanding | 136.11M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 64.92% |
| Owned by Institutions (%) | 21.84% |
| Float | 36.78M |
Valuation Ratios
The trailing PE ratio is 50.00 and the forward PE ratio is 43.70. Eris Lifesciences's PEG ratio is 2.96.
| PE Ratio | 50.00 |
| Forward PE | 43.70 |
| PS Ratio | 8.45 |
| PB Ratio | 7.34 |
| P/FCF Ratio | n/a |
| PEG Ratio | 2.96 |
Enterprise Valuation
| EV / Earnings | 55.26 |
| EV / Sales | 9.35 |
| EV / EBITDA | 28.41 |
| EV / EBIT | 39.10 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 3.76 |
| Debt / FCF | n/a |
| Interest Coverage | 4.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 7.36% |
| Revenue Per Employee | 6.21M |
| Profits Per Employee | 1.05M |
| Employee Count | 3,620 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +61.63% |
| 50-Day Moving Average | 1,307.26 |
| 200-Day Moving Average | 1,018.65 |
| Relative Strength Index (RSI) | 58.10 |
| Average Volume (20 Days) | 488,490 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Eris Lifesciences had revenue of INR 22.47 billion and earned 3.80 billion in profits. Earnings per share was 27.92.
| Revenue | 22.47B |
| Gross Profit | 17.65B |
| Operating Income | 5.37B |
| Pretax Income | 4.34B |
| Net Income | 3.80B |
| EBITDA | 7.40B |
| EBIT | 5.37B |
| Earnings Per Share (EPS) | 27.92 |
Balance Sheet
The company has 14.01 billion in cash and 27.81 billion in debt, giving a net cash position of -13.81 billion or -101.44 per share.
| Cash & Cash Equivalents | 14.01B |
| Total Debt | 27.81B |
| Net Cash | -13.81B |
| Net Cash Per Share | -101.44 |
| Equity (Book Value) | 32.22B |
| Book Value Per Share | 190.24 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 78.54%, with operating and profit margins of 23.92% and 16.93%.
| Gross Margin | 78.54% |
| Operating Margin | 23.92% |
| Pretax Margin | 19.32% |
| Profit Margin | 16.93% |
| EBITDA Margin | 32.92% |
| EBIT Margin | 23.92% |
| FCF Margin | n/a |
Dividends & Yields
Eris Lifesciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
| Earnings Yield | 2.00% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |